StockNews.com assumed coverage on shares of BIOLASE (NASDAQ:BIOL – Free Report) in a research note released on Wednesday. The brokerage issued a sell rating on the medical technology company’s stock.
Several other research firms have also recently issued reports on BIOL. Benchmark reiterated a speculative buy rating and issued a $0.40 price objective on shares of BIOLASE in a research report on Monday, August 12th. Ascendiant Capital Markets cut their price objective on BIOLASE from $3.50 to $2.00 and set a buy rating for the company in a research report on Tuesday, September 3rd.
View Our Latest Stock Analysis on BIOL
BIOLASE Stock Performance
BIOLASE (NASDAQ:BIOL – Get Free Report) last issued its quarterly earnings results on Thursday, August 8th. The medical technology company reported ($0.08) earnings per share for the quarter. The company had revenue of $11.56 million for the quarter. BIOLASE had a negative return on equity of 1,782.73% and a negative net margin of 41.65%.
Institutional Investors Weigh In On BIOLASE
An institutional investor recently raised its position in BIOLASE stock. Virtu Financial LLC boosted its stake in shares of BIOLASE, Inc. (NASDAQ:BIOL – Free Report) by 1,068.0% in the first quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 143,537 shares of the medical technology company’s stock after purchasing an additional 131,248 shares during the quarter. Virtu Financial LLC owned approximately 0.43% of BIOLASE worth $27,000 at the end of the most recent reporting period. Institutional investors and hedge funds own 8.79% of the company’s stock.
About BIOLASE
BIOLASE, Inc, together with its subsidiaries, develops, manufactures, markets, and sells laser systems for dental practitioners and their patients in the United States and internationally. Its dental laser systems allow dentists, periodontists, endodontists, pediatric dentists, oral surgeons, and other dental specialists to perform a range of minimally invasive dental procedures, including cosmetic, restorative, and complex surgical applications.
Featured Stories
- Five stocks we like better than BIOLASE
- Low PE Growth Stocks: Unlocking Investment Opportunities
- CarMax’s Impressive Rally: What Investors Should Watch Next
- Asset Allocation: The Key to a Successful Portfolio. Are You Paying Attention to Yours?
- MarketBeat Week in Review – 9/23 – 9/27
- What Makes a Stock a Good Dividend Stock?
- Wake Up to This Biotech Stock That Still Has Big Potential Upside
Receive News & Ratings for BIOLASE Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BIOLASE and related companies with MarketBeat.com's FREE daily email newsletter.